- Open Access
Evaluation of the efficacy and safety of Melatonin in moderately ill patients with COVID-19: A structured summary of a study protocol for a randomized controlled trial
Trials volume 21, Article number: 882 (2020)
We will evaluate the efficacy and safety of Melatonin, compared to the standard therapeutic regimen on clinical symptoms and serum inflammatory parameters in patients with confirmed COVID-19, who are moderately ill.
This is a single-center, randomized, double-blind, placebo-controlled clinical trial with a parallel-group design conducted at Shahid Mohammadi Hospital, Bandar Abbas, Iran.
All patients admitted to Severe Acute Respiratory Syndrome Departments of Shahid Mohammadi Hospital, Bandar Abbas, Iran will be screened for the following criteria.
1. Age ≥20 years
2. Confirmed SARS-CoV-2 diagnosis (positive polymerase chain reaction).
3. Moderate COVID-19 pneumonia (via computed tomography and or X-ray imaging), requiring hospitalization.
4. Hospitalized ≤48 hours.
5. Signing informed consent and willingness of the participant to accept randomization to any assigned treatment arm.
1. Underlying diseases, including chronic hypertension, diabetes mellitus, seizure, depression, chronic hepatitis, cirrhosis, and cholestatic liver diseases.
2. Severe and critical COVID-19 pneumonia.
3. Use of warfarin, corticosteroids, hormonal drugs, alcohol, other antiviral and investigational medicines, and illegal drugs (during the last 30 days).
4. History of known allergy to Melatonin.
5. Pregnancy and breastfeeding.
Intervention and comparator
Intervention group: The standard treatment regimen for COVID-19, according to the Iranian Ministry of Health and Medical Education's protocol, along with Melatonin capsules at a dose of 50 mg daily for a period of seven days.
Control group: The standard therapeutic regimen for COVID-19 along with Melatonin-like placebo capsules at a dose of one capsule daily for a period of seven days.
Both Melatonin and placebo capsules were prepared at the Faculty of Pharmacy and Pharmaceutical Sciences, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.
The primary outcomes are the recovery rate of clinical symptoms and oxygen saturation as well as improvement of serum inflammatory parameters, including C-reactive protein, tumor necrosis factor-alpha (TNF-ɑ), interleukin-1β (IL-1β), and IL-6 within seven days of randomization.
The secondary outcomes are the time to improve clinical and paraclinical features along with the incidence of serious adverse drug reactions within seven days of randomization.
Included patients will be allocated to one of the study arms using block randomization in a 1:1 ratio (each block consists of 10 patients). This randomization method ensures a balanced allocation between the arms during the study. A web-based system will generate random numbers for the allocation sequence and concealment of participants. Each number relates to one of the study arms.
All study participants, clinicians, nurses, research coordinators, and those analyzing the data are blinded to the group assignment.
Numbers to be randomized (sample size)
A total of 60 patients randomized into two groups (30 in each group).
The trial protocol is Version 1.0, August 14, 2020. Recruitment began August 22, 2020, and is anticipated to be completed by November 30, 2020.
The trial protocol has been registered in the Iranian Registry of Clinical Trials (IRCT). The registration number is “IRCT20200506047323N5”. The registration date was 14 August 2020.
The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting the dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
Availability of data and materials
The corresponding author has access to the final trial information, and the data will be available on reasonable request (Contact: M.firstname.lastname@example.org).
We would like to thank the assistance of VANA Darou Gostar Pharmaceutical Company, for preparing the Melatonin raw material. The VANA Darou Gostar Pharmaceutical Company has no role in the trial design, the intervention procedures, collection, evaluation, and analysis of data. The authors would also like to thank all the clinicians, nurses, and medical staff who dedicated their time and efforts to managing patients during the COVID-19 pandemic.
This trial has been supported by Hormozgan University of Medical Sciences, Bandar Abbas, Iran (grant no. 990191). The funders have no role in the trial design, the intervention procedures, collection, evaluation, and analysis of data.
Ethics approval and consent to participate
The RCT protocol was approved by the Ethics Committee of Hormozgan University of Medical Sciences (Ethics committee reference number: IR.HUMS.REC.1399.130) on August 02, 2020. The investigators declare the trial has received ethical approval from the appropriate ethical committee, as described above. All participants freely signed informed consent before randomization.
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Ziaei, A., Davoodian, P., Dadvand, H. et al. Evaluation of the efficacy and safety of Melatonin in moderately ill patients with COVID-19: A structured summary of a study protocol for a randomized controlled trial. Trials 21, 882 (2020). https://doi.org/10.1186/s13063-020-04737-w
- Randomised controlled trial
- Inflammatory responses
- Clinical symptoms